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Br J Pharmacol. 2019;1–14.Background and Purpose: Human malignant hyperthermia (MH) syndrome is
induced by volatile anaesthetics and involves increased levels of cystathionine β‐
synthase (CBS)‐derived H2S within skeletal muscle. This increase contributes to skel-
etal muscle hypercontractility. Kv7 channels, expressed in skeletal muscle, may be a
molecular target for H2S. Here, we have investigated the role of Kv7 channels in MH.
Experimental Approach: Skeletal muscle biopsies were obtained from MH‐
susceptible (MHS) and MH‐negative (MHN) patients. Immunohistochemistry, RT‐
PCR, Western blot, and in vitro contracture test (IVCT) were carried out. Develop-
ment and characterization of primary human skeletal muscle cells (PHSKMC) and
evaluation of cell membrane potential were also performed. The persulfidation state
of Kv7 channels and polysulfide levels were measured.
Key Results: Kv7 channels were similarly expressed in MHN and MHS biopsies. The
IVCT revealed an anomalous contractility of MHS biopsies following exposure to the
Kv7 channel opener retigabine. Incubation of negative biopsies with NaHS, prior to
retigabine addition, led to an MHS‐like positive response. MHS‐derived PHSKMC
challenged with retigabine showed a paradoxical depolarizing effect, compared with
the canonical hyperpolarizing effect. CBS expression and activity were increased in
MHS biopsies, resulting in a major polysulfide bioavailability. Persulfidation of Kv7.4
channels was significantly higher in MHS than in MHN biopsies.
Conclusions and Implications: In skeletal muscle of MHS patients, CBS‐derived
H2S induced persulfidation of Kv7 channels. This post‐translational modification
switches the hyperpolarizing activity into depolarizing. This mechanism can contrib-
ute to the pathological skeletal muscle hypercontractility typical of MH syndrome.e; BKCa, big conductance calcium‐activated K channels; CBS, cystathionine β‐synthase; CSE, cystathionine γ‐lyase; H2Sn, polysulfides;
sium channels; MH, malignant hyperthermia; MHN, malignant hyperthermia negative; MHS, malignant hyperthermia susceptible;
tal muscle
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2 VELLECCO ET AL.BJPWhat is already known
• An increase in CBS‐derived H2S within SKM occurs in
human malignant hyperthermia.
• This contributes to SKM hypercontractility, one of the
features of MH.
What this study adds
• Augmented levels of CBS‐derived H2S drive
persulfidation of Kv7 channels.
• This post‐translational modification overturns the Kv7
activity.
What is the clinical significance
• The paradoxical Kv7 channel activity participates in the
pathological hypercontractility of SKM.
• Evaluation of H2S content and Kv7 persulfidation could
help to diagnose malignant hyperthermia.1 | INTRODUCTION
Malignant hyperthermia (MH) is an inherited pharmacogenetic disor-
der of skeletal muscle (SKM) characterized by a massive and uncon-
trolled release of calcium within SKM triggered by volatile inhalation
anaesthetics (halothane, isoflurane, enflurane, sevoflurane, and
desflurane), depolarizing muscle agents (succinylcholine), or extreme
physical activity in a hot environment (Hopkins et al., 2015; Brislin &
Theroux, 2013; Rosenberg, Pollock, Schiemann, Bulger, & Stowell,
2015). In susceptible subjects, MH syndrome appears anytime during
anaesthesia or early post‐operative period, and if it is not rapidly rec-
ognized and promptly controlled, it can be fatal. It is characterized by
tachycardia and muscle rigidity, followed by metabolic acidosis, rhab-
domyolysis and a rapid increase of body temperature. The sustained
muscle contraction causes a rapid depletion of ATP, oxygen consump-
tion, and heat production, with body temperatures reaching 43–44°C.
All these events lead to cyanosis, hypermetabolic crisis, cardiac and/or
renal dysfunction and disseminated intravascular coagulation (Hop-
kins, 2011; Kim, 2012). The reported incidence of MH has been esti-
mated between 1:5,000 and 1:50,000 exposures to anaesthetics
with a mortality rate around 10%. Unfortunately, the morbidity rate
is much higher, around 35% (Kim, 2012; Stratman, Flynn, & Hatton,
2009). Genetic studies have identified several loci within the human
genome that are linked to MH susceptibility, among them MH suscep-
tible (MHS)1, associated with ryanodine 1 receptor gene (RyR1) muta-
tions on chromosome 19q13.1, and MHS3, associated with
CACNA2D1 gene mutations on chromosome 1q32, which codes for
the α2∂ subunit of dihydropyridine‐sensitive L‐type calcium channel
(Anderson‐Pompa et al., 2008; Rosenberg & Rueffert, 2011). To date,
more than 300 different mutations of RyR1 gene have been associated
to MH susceptibility. However, much less than 50% of susceptible
subjects display RyR1 gene mutations (Jurkatt‐Rott, McCarthy, &
Lehmann‐Horn, 2000; Girard et al., 2002). For these reasons, the gold
standard for MH diagnosis relies on a bioassay defined “in vitro con-
tracture test” (IVCT; Hopkins et al., 2015). IVCT is an invasive diagnos-
tic procedure that requires a biopsy of the vastus group of quadriceps
muscle mounted in an organ bath in order to assess the SKM contrac-
tility in response to two different triggers: halothane and caffeine.
According to the European group protocol for investigation of MH
susceptibility, the diagnosis depends on the increased muscle contrac-
ture observed, which unveils the defect of excitation–contraction cou-
pling mechanism. It is important to note that the majority of
susceptible subjects have a healthy phenotype and it is, therefore,
impossible to diagnose MH susceptibility without the IVCT procedure.
Hydrogen sulfide (H2S) is produced in several tissues and organ
systems and in animals and humans by both enzymic (the major
portion) and non‐enzymic pathways. In mammals, H2S biosynthesis
is controlled by a variety of enzymes, widely expressed throughout
the body (Szabo & Papapetropoulos, 2017; Wallace & Wang,
2015). The best characterized H2S‐generating enzyme is cystathio-
nine β‐synthase (CBS), which is the main source of H2S in the
CNS (Abe & Kimura, 1996; Miles & Kraus, 2004), although CBS is
abundantly expressed also in peripheral tissues (Bucci et al., 2014;Fiorucci, Distrutti, Cirino, & Wallace, 2006; Hosoki, Matsuki, &
Kimura, 1997; Szabo et al., 2013; Vellecco et al., 2016; Zhang,
Pan, Yang, Xiao, & Yu, 2013). Cystathionine γ‐lyase (CSE) is the
main H2S‐generating enzyme in the vasculature and has also been
found in many other parts of the body (Bucci et al., 2012; Cirino,
Vellecco, & Bucci, 2017; Fiorucci et al., 2006; Vellecco et al., 2016;
Zhao, Zhang, Lu, & Wang, 2001). CBS and CSE are involved in dif-
ferent steps of the transsulfuration pathway, although both enzymes
need the amino acid L‐cysteine as substrate and require pyridoxal‐5‐
phosphate as a co‐factor (Kabil & Banerjee, 2014; Kimura, 2014). 3‐
Mercaptopyruvate sulfurtransferase (3‐MST) is the third H2S‐gener-
ating enzyme, and it is pyridoxal‐5‐phosphate independent and uses
3‐mercaptopyruvate as substrate. 3‐MST is expressed in vasculature
and in smooth muscle component of several organs (Modis,
Panopoulos, Coletta, Papapetropoulos, & Szabo, 2013; Shibuya,
Mikami, Kimura, Nagahara, & Kimura, 2009; Vellecco et al., 2016).
The presence of hydrogen sulfide (H2S) signalling in SKM has been
recently identified, and its role in SKM function is currently under
investigation (see Vellecco, Armogida, & Bucci, 2018). We and others
have shown that SKM expresses the three constitutive enzymes
responsible for H2S biosynthesis in rats (Chen et al., 2010; Du, Li,
Yang, Li, & Jin, 2013) and humans (Islam, Polhemus, Donnarumma,
Brewster, & Lefer, 2015; Vellecco et al., 2016) that actively generate
H2S. In this context, we have recently demonstrated that in MHS
subjects, there is an increase in CBS‐derived H2S within the SKM
that contributes to MH‐related hypercontractility (Vellecco et al.,
2016). Among the possible molecular targets of H2S, the voltage‐gated
potassium channels Kv7.1–Kv7.5 (or KCNQ1–KCNQ5) have been iden-
tified in several cell types regulating the resting membrane potential
and electrical excitability (Di Cesare Mannelli et al., 2017; Martelli
et al., 2013; Miceli, Soldovieri, Martire, & Taglialatela, 2008). In
VELLECCO ET AL. 3BJPparticular, in SKM cells, Kv7 channels promote myogenesis as well as
preventing statin‐induced toxicity (Iannotti et al., 2010; Roura‐Ferrer,
Solé, Martínez‐Mármol, Villalonga, & Felipe, 2008). Notably, among
Kv7 channels, the Kv7.4 channels are the most highly expressed, in both
murine and human SKM cells (Iannotti et al., 2014; Iannotti, Barrese,
Formisano, Miceli, & Taglialatela, 2013).
However, the mechanism by which H2S affects the activity of Kv7
channels remains unknown. Therefore, in order to better define the
molecular basis of H2S‐related MH hypercontractility, this study inves-
tigated the involvement of Kv7 channels in the MH syndrome.2 | METHODS
2.1 | Human skeletal muscle biopsies
This research has been carried out in accordance with the Declara-
tion of Helsinki (2013) of the World Medical Association. The Ethical
Committee of the Institution (Cardarelli Hospital Centre for the
Study of Malignant Hyperthermia) approved the study and its proto-
cols (4/13 prot. 358). The subjects have given written informed con-
sent. The Cardarelli Hospital Center for the Study of Malignant
Hyperthermia opened in December 1989. In these 29 years
(1989–2018), 2,650 patients have been identified . An accurate
anamnesis has been carried out in order to identify potential muscu-
lar disorders, problems occurring during previous exposure to gen-
eral anaesthetics, and sudden neonatal death. Contextually, a
clinical assessment revealing muscle skeletal alterations, such as
cifoscoliosis, club foot, and flying scapulas, has been performed
together with clinical evaluation of squint, cryptorchidism, palpebral
ptosis, inguinal, and/or dischernia. As eligible subjects, 930 patients
agreed to a muscle biopsy inorder to carry out the IVCT test. Of
these patients, 67% have been diagnosed as MH negative (MHN;
negative diagnosis; 623 subjects) and 15% diagnosed as MH
suceptible(MHS; susceptibility diagnosis; 136). During the last three
years (2015–2018), 150 IVCT tests were performed and 65% were
diagnosed as MHN diagnosed (98 subjects) and 15% as MHS (23
subjects). The present study has been performed on 20 MHS and
on 50 MHN biopsies not required for IVCT, that is, after diagnosis
has been made (male and female with age >20 years) over 18 months
from December 2016 to June 2018. All the surgical procedures have
been performed at the Cardarelli Hospital.2.2 | Development and full characterization of
primary human skeletal muscle cell culture
Sterile muscle pieces from MHN and MHS biopsies were used. Briefly,
pieces were cut in bundles, and each bundle was transferred to a ster-
ile cell culture insert within a six‐well plate containing DMEM (4.5 g·L
−1 glucose) supplemented with 20% FBS, 7‐mM HEPES, 4 μg·ml−1
insulin, 1% (vol/vol) antibiotics (penicillin/streptomycin and
gentamycin), 2‐mM L‐glutamine, and 1% (vol/vol) amphotericin B
according to Censier, Urwyler, Zorzato, & Treves, (1998), with somemodifications. After 8–10 days, satellite cells could be clearly seen
growing attached to the insert surrounding the biopsy fragment. The
culture insert was then removed, and after 15 days, the medium was
changed in DMEMwithout amphotericin B. Cells were kept in an incu-
bator at 37°C under 5% CO2, until confluence was reached. For the
evaluation of cell membrane potential, the cells were exposed to dif-
ferentiation medium, DMEM supplemented with 10% horse serum
for 3 days in order to promote the fusion of myogenic satellite cells
into myotubes.
2.3 | Evaluation of cell membrane potential in
response to potassium channel modulation in primary
human skeletal muscle cells
The hyperpolarizing and the depolarizing effects have been evaluated
on MHN‐derived and MHS‐derived primary human SKM cells
(PHSKMC) by a fluorimetric method (Martelli et al., 2013). Briefly,
PHSKMC have been seeded onto a 96‐well black plate, clear bottom,
at density of 20 × 103 per well, and after 24 hr, the culture medium
has been replaced, and cells have been incubated for 72 hr with the
differentiation medium. After 72 hr, the differentiation medium was
removed, and cells incubated for 1 hr with an appropriate buffer
(HEPES 20 mM, NaCl 120 mM, KCl 2 mM, CaCl2
.2H2O 2 mM,
MgCl2
.6H2O 1 mM, and glucose 5 mM, pH 7.4, at room temperature)
containing the bisoxonol dye bis‐(1,3‐dibutylbarbituric acid) DiBac4(3)
at 2.5 μM. This membrane potential‐sensitive dye DiBac4(3) allows a
non‐electrophysiological measurement of cell membrane potential; in
fact, this lipophylic and negatively charged oxonol dye shuffles
between cellular and extracellular fluids in a membrane potential‐
dependent manner (following the Nernst equation), thus allowing to
assess changes in membrane potential by means of fluorimetric
recording. An increase of fluorescence, corresponding to an inward
flow of the dye, reflects a membrane depolarization, whereas a
decrease in fluorescence, due to an outward flow of the dye, is linked
to membrane hyperpolarization. The fluorimetric recording is carried
out at excitation and emission wavelengths of 488 and 520 nm
respectively. After the assessment of baseline fluorescence, when
required by the experimental protocol, an excess of a well‐known
H2S donor, NaHS 3 mM, or its vehicle was incubated with the PHSKM
cells for 20 min before the addition of the potassium channel modula-
tors. We used the KATP activator cromakalim (10 μM) and the KATP
blocker glibenclamide (10 μM); the BKCa activator NS1619 (10 μM)
and the BKCa blocker iberiotoxin (100 nM); the Kv7 activator
retigabine (50 μM) and the Kv7 blocker XE991 (10 μM). The relative
fluorescence decrease or increase, linked to hyperpolarizing or
depolarizing effects of the potassium channel modulators, was calcu-
lated as follows:
Ft − F0ð Þ=F0;
where F 0 is the basal fluorescence before the addition of the
tested compounds and F t is the fluorescence at time t after their
administration. Results are expressed as the means (±SEM) of
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pounds during the 35 min of the experiment. The experiments (n = 5)
were carried out using six replicates.2.4 | Immunohistochemistry
The antibody‐based procedures used in this study comply with the
recommendations made by the British Journal of Pharmacology
(Alexander et al., 2018). Bundles of SKM from MHN or MHS sub-
jects were fixed in neutral buffered formalin and then embedded in
paraffin. Sections (4 μm) were stained with haematoxylin and eosin
and analysed under light microscopy. MHN‐derived and MHS‐
derived PHSKMC were rinsed twice with ice‐cold PBS and centri-
fuged at 200× g for 5 min. Then the cell population was smeared,
fixed using standard fixative for cytology (citofix), and processed by
a modular automated tissue processor (Leica ASP300S). Once
embedded in a paraffin block, cells were cut into 3 μm sections,
using a microtome, floated in a 40°C water bath containing distilled
water, and mounted onto STARFROST slides. The slides were
analysed by using a fully automated staining instrument Benchmark
Ultra Ventana coupled to the ultraView Universal DAB Detection
Kit (Ventana). In details, for each slide, Ventana labels have been
printed, which include a unique barcode containing all protocol infor-
mation. The slides have been loaded onto the BenchMark carousel
and read by the Ventana Barcode Reader. The automated Bench-
Mark system puts the slides through a series of user‐defined de‐
paraffinization and antigen retrieval steps before starting with the
antibody staining. The primary antibodies, such as anti‐desmin
(Ventana), anti‐myogenin (Ventana), and SKM‐specific α‐actin
(Ventana), were applied automatically in a pre‐diluted dispenser.
The antibody for Kv7.4 channels (KCNQ4; 1:100; Elabscience Hous-
ton, Texas) was manually titrated onto the slide. For this antibody, a
specific protocol was carried out: de‐paraffinization at 72°C, anti-
genic unmasking at 95°C for 8 min, enzymic digestion with
protease‐2 for 4 min, incubation with primary antibody for 40 min,
and post‐counterstain with haematoxylin for 8 min. The images were
taken with an Olympus DP21 video camera connected to an Olym-
pus BX43 microscope using Olympus Stream image analysis
software.2.5 | Western blotting
Muscle biopsies obtained from MHN and MHS patients and MHN‐
PHSKMC and MHS‐PHSKMC were homogenized in RIPA buffer as
previously described (Vellecco et al., 2016). Briefly, denatured pro-
teins (40 μg) were separated on 10% SDS polyacrylamide gels and
transferred to PVDF membranes. Membranes were blocked in PBS
containing 0.1% vol/vol Tween‐20 and 3% wt/vol non‐fat dry milk
for 30 min, followed by overnight incubation at 4°C with rabbit
polyclonal Kv7.4 antibody (1:1,000). Membranes have been exten-
sively washed in PBS containing 0.1% vol/vol Tween‐20 prior to
incubation with HRP‐conjugated secondary antibody for 2 hr.Following incubation, membranes have been washed and developed
using ImageQuant‐400 (GE Healthcare, USA). The target
protein band intensity has been normalized relative to the intensity
of the housekeeping protein GAPDH (1:5,000, Sigma‐Aldrich,
Milan, Italy).2.6 | RNA purification and quantitative real‐time
PCR
Total RNA was isolated from human samples, using the TRI Reagent
(Sigma‐Aldrich, Milan, Italy), according to the manufacturer's instruc-
tions, followed by spectrophotometric quantization as previously
described (Panza et al., 2015). Final preparation of RNA was consid-
ered DNA‐free and protein‐free if the ratio between readings at
260/280 nm was ≥1.7. Isolated mRNA was reverse transcribed by
use of iScript Reverse Transcription Supermix for RTqPCR (Bio‐Rad,
Milan, Italy). The quantitative real‐time PCR was carried out in
CFX384 real‐time PCR detection system (Bio‐Rad, Milan, Italy) with
specific primers by the use of SYBR Green master mix kit (Bio‐Rad,
Milan, Italy). Samples were amplified simultaneously in triplicate in
one‐assay run with a non‐template control blank for each primer pair
to control for contamination or primer dimers formation, and the ct
value for each experimental group was determined. The housekeeping
gene (ribosomal protein S16) was used as an internal control to
normalize the ct values, using the 2−ΔCt formula. Primers sequence
(5′–>3′) hKv7.1 fw: GCGTCTCCATCTACAGCACG; hKv7.1 rev:
GAAGTGGTAAACGAAGCATTTCC; hKv7.2 fw: ATCCTGGAAATCGT
GACTATCGT; hKv7.2 rev: TTCCGGGCAAACTTGAGCC; hKv7.3 fw:
AGAGGTGGATGCACAAGGAGA; hKv7.3 rev: CTTCCCACGTTTTG
GGTGTC; hKv7.4 fw: GTGATGATCGTGGTTTTCGGC; hKv7.4 rev:
CGATGAAGTCGATGACACAGAA; hKv7.5 fw: CAGGGGCCAGAGTA
TTAAGAGC; and hKv7.5 rev: CTTCTGCACTTTGGTGGGACT.2.7 | In vitro contracture test
The procedure has been performed accordingly to the “European
Malignant Hyperthermia Group (EMHG) guidelines for investigation
of malignant hyperthermia susceptibility” (www.emhg.org). Briefly,
the muscular biopsy of the vastus group of the quadriceps muscle
was taken under regional anaesthesia, under a femoral nerve block
with 2% carbocaine. A 3‐ to 5‐cm incision was made, 4–5 muscular
bundles of 15‐ to 25‐mm length, and 2‐ to 3‐mm thickness have been
dissected within 15 min and quickly transferred to Krebs–Ringer solu-
tion with the following composition: NaCl 118.1 mM, KCl 3.4 mM,
MgSO4 0.8 mM, KH2PO4 1.2 mM, glucose 11.1 mM, NaHCO3
25.0 mM, and CaCl2 2.5 mM; pH 7.4. The muscle samples were
transported at room temperature from the operating theatre to the
laboratory within 30 min. Once in the laboratory, the muscle bundles
in Krebs‐Ringer were oxygenated with carbogen (95% oxygen and
5% carbon dioxide mixture), which continued for the duration of the
whole procedure. The time from biopsy to the end of the tests did
not exceed 5 hr. Each bundle was tied on both ends and mounted
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that the lower end was fixed and the upper end was connected to
an isometric transducer (IsometricTransducer 1–10 g, Ugo Basile) with
a resting tension of 0.2 g (2 mN). The length between sutures was
measured and defined as the initial length. After leaving the tissue
for 5 min at initial length, an electrical stimulus was applied (Stimu-
lator LI 12006, Ugo Basile) with a 1‐ to 2‐ms supramaximal stimulus
at a frequency of 0.2 Hz. During electrical stimulation, the muscle
was stretched slowly to 150 ± 10% of initial length; this new length
was considered to be the optimal length. The muscle was allowed to
stabilize at the optimal length for at least 15 min and until baseline
force did not vary more than 0.2 g (2 mN) within a 10‐min period.
The signal was amplified, continuously recorded, and analysed by
PowerLab System. After a 20‐min equilibration, two different proto-
cols were applied. One requires the addition of progressive concen-
trations of caffeine (0.5, 1.0, 1.5, 2.0, 3.0, and 4.0 mM) to the
isolated organ bath; the other one requires the addition of progres-
sive concentrations of halothane (0.5%, 1%, 2%, and 3%) in the iso-
lated organ bath. An increase in resting tension of at least 0.2 g
(2 mN) has been considered significant and allows a positive diagno-
sis to be made.2.8 | Malignant hyperthermia susceptibility diagnosis
According to EMHG guidelines (Hopkins et al., 2015), a positive test
and therefore a diagnosis depends on the increased resting tension
of the tested muscle specimen: The threshold value for susceptibility
is established as an increase of ≥0.2 g above the lowest resting ten-
sions, as follows (Figure S1):
• MHShc (formerly MHS, MH‐susceptible muscle): a caffeine thresh-
old at caffeine concentration of 2.0 mM or less and a halothane
threshold concentration at 0.44 mM or less.
• MHN (MH non‐susceptible muscle): A caffeine threshold at a caf-
feine concentration of 3 mM or more and halothane threshold con-
centration above 0.44 mM.
• MHSh (formerly MHE, MH equivocal muscle): The suffix has been
added to indicate an abnormal response to halothane only.
• MHSc (formerly MHE, MH equivocal muscle): The suffix has been
added to indicate an abnormal response to caffeine only.2.9 | In vitro study
The MHN and MHS biopsies not required for IVCT, that is, after
diagnosis was made, were mounted in an isolated organ bath con-
nected to an isometric transducer (Isometric Transducer 1–10 g,
Ugo Basile) with a resting tension of 0.2 g. The muscle was allowed
to stabilize for at least 15 min. The signal was amplified, continu-
ously recorded, and analysed by PowerLab System (ADInstruments
Lab Chart 8.0). To evaluate the possible involvement of Kv7 chan-
nels in muscle functionality, both MHN and MHS bundles have beenexposed to retigabine (1 mM), and the changes in resting tension
were carefully observed for 15 min. In another set of experiments,
MHN tissues were incubated for 5 min with NaHS (3 mM) or vehicle
(dH2O), and then retigabine (1 mM) was added to the organ bath The
changes in bundle resting tension were similarly monitored
for 15 min.2.10 | Protein persulfidation
Persulfidation has been detected using a modified biotin switch assay
(Bibli, Hu, et al., 2018). In brief, samples were precipitated with 20%
trichloroacetic acid and stored at −80°C for 24 hr. Precipitates were
washed with 10% and 5% trichloroacetic acid and then centrifuged
(16,000× g, 30 min, 4°C) before being resuspended in HENS buffer
(250‐mM HEPES–NaOH, 1‐mM EDTA, 0.1‐mM neocuproine,
100‐μM deferoxamine, and 2.5% SDS) containing 20mM
methanethiosulfonate and protease and phosphatase inhibitors. Ace-
tone precipitation was performed, and pellets were resuspended in
300‐μl qPerS‐SID lysis buffer (6‐M urea, 100‐mM NaCl, 2% SDS, 5‐
mM EDTA, and 200‐mM Tris, pH 8.2, 50‐mM iodoacetyl–PEG2–
biotin, and 2.5‐mM dimedone), sonicated, and incubated for 2 hr at
room temperature in the dark. Lysates (500 μg) were precipitated with
acetone, and protein pellets were resuspended in 50‐μl Tris–HCl
(50 mM, pH 8.5) containing guanidinium chloride (GdmCl 6 mM) and
incubated at 95°C for 5 min. A negative control was generated for
each sample by adding DTT (1 mM) during biotin cross‐linking. Ten
per cent of the sample was immediately boiled at 95°C by addition
of 3% SDS, 1% β‐mercaptoethanol, 8‐M urea, and 0.005%
bromophenol blue and used for the identification of the levels of
Kv7.4 channels among the samples (input). Ninety per cent of the sam-
ples was used for biotin immunoprecipitation overnight (4°C) using a
high‐capacity streptavidin resin. Elution was performed by addition
of 3% SDS, 1% β‐mercaptoethanol, 8‐M urea, and 0.005%
bromophenol blue in PBS for 15 min at room temperature followed
by 15 min at 95°C. Persulfidated proteins were then detected by
SDS‐PAGE and Western blotting with a specific antibody against
Kv7.4 channels.2.11 | Measurement of H2S and polysulfides, and
assay of CBS enzymic activity
The tissue polysulfides were measured based on the Sulfane Sulfur
Probe 4 (SSP4) selective reaction, as previously described (Bibli, Luck,
et al., 2018). This method traps selectively H2S, and derivatives such
as H2S‐related sulfane sulfur compounds, including persulfides (R–S–
SH) and polysulfides (R–Sn–SH or R–S–Sn–S–R), and subsequently,
the concentrations are calculated from the LC/MS/MS results. In brief,
1 mg of human tissue was lysed in ice‐cold RIPA buffer (50‐mM Tris–
HCl, pH 7.5, 150‐mM NaCl, 25‐mM NaF, 10‐mM Na4P2O7, 1% Triton
X‐100, and 0.5% sodium deoxycholate) in the absence of SDS but in
the presence of protease and phosphatase inhibitors. Protein
(0.5 mg) was used, and substrates of CBS (we only assayed for CBS
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(100 μM) and L‐cysteine (100 μM) along with pyridoxal phosphate
(10 μM) and SSP4 (10 μM), were added to the samples. Samples were
then incubated for 60 min at 37°C. Thereafter, the tissue supernatant
was collected, and floating cells were removed by centrifugation
(16,000× g, 10 min, 4°C). The specific products of the reaction of
H2S with SPP4 were quantified by LC/MS/MS using a 1290 Infinity
UHPLC system (Agilent Technologies Deutschland GmbH, Waldbronn,
Germany) and a C18 Phenomenex Kinetex (150 × 2.1 mm) column,
protected by a Phenomenex C18 guard cartridge. For the quantifica-
tion of H2Sn production, standard curves for fluorescein and SSP4
have been generated in RIPA buffer.2.12 | Data and statistical analysis
The data and statistical analysis comply with the recommendations
of the British Journal of Pharmacology on experimental design and
analysis in pharmacology (Curtis et al., 2018). The data have been
expressed as mean ± SEM. The number of replicates has been at
least (n) of five per group except for three experiments performed
on human MHS sample (Figures 2 and 4b,c). This is due to the low
incidence of the syndrome (being a rare disease) coupled to the dif-
ficulty of obtaining human tissue from MHS subjects which was not
required for diagnosis. For these figures, statistical analysis of the
dataset was not undertaken. The comparisons between groups were
performed using Student's t test or one‐way ANOVA followed by
Bonferroni or Dunnett's post hoc tests, as appropriate. Post hoc
tests were performed when ANOVAs indicated that a significantFIGURE 1 Full characterization of primary human skeletal muscle cells de
and malignant hyperthermia‐susceptible (MHS; susceptible patients) biopsie
MHN and MHS subjects shows no significant difference between the two
The pictures are representative of n = 6 for each group. (c–e) Immunohist
strong positivity to actin‐specific muscle, desmin, and myogenin, respective
each groupdifference existed between the groups. Data have been considered
statistically significant when a value of P < .05 has been achieved.
GraphPad Prism 5 (GraphPad Software Inc., San Diego, USA) has
been employed for data analysis.2.13 | Materials
All reagents for Krebs solution preparation were purchased from Carlo
Erba Reagents (Milan, Italy). Caffeine, Tris–HCl, Triton‐X, sodium
deoxycholate, sodium chloride, EDTA, protease inhibitor cocktail,
sodium fluoride, DMSO, bisoxonol dye bis‐(1,3‐dibutylbarbituric acid)
DiBac4(3), cromakalim, glibenclamide, NS1619, iberiotoxin, and all
reagents for culture cells were purchased from Sigma‐Aldrich (Milan,
Italy). All the drugs were dissolved in distilled H2O, except for
DiBac4(3), cromakalim, glibenclamide, NS1619, and iberiotoxin, which
were dissolved in DMSO. Retigabine and XE991 have been obtained
from Tocris (Bristol, UK) and dissolved in DMSO. Iodoacetyl–PEG2–
biotin and high‐affinity streptavidin resin were purchased from
Thermo Scientific (Heidelberg, Germany). SSP4 was purchased from
Dojindo (GERBU Biotechnik GmbH, Heidelberg, Germany).2.14 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corre-
sponding entries in http://www.guidetopharmacology.org, the com-
mon portal for data from IUPHAR/BPS Guide to PHARMACOLOGY
(Harding et al., 2018), and are permanently archived in the Conciserived from malignant hyperthermia‐negative (MHN; negative patients)
s. (a, b) Haematoxylin and eosin staining of muscle fibres derived from
groups. Left panel, 10× magnification; right panel, 40× magnification.
ochemical staining of primary human skeletal muscle cells reveals a
ly (25× magnification). The photographs are representative of n = 6 for
FIGURE 2 Primary human skeletal muscle cells (PHSKMC) derived from malignant hyperthermia‐negative (MHN; negative patients) and
malignant hyperthermia‐susceptible (MHS; susceptible patients) biopsies do not reveal any difference in Kv7.4 channel expression. (a)
Immunohistochemical staining of PHSKMC derived from both MHN and MHS shows a cytoplasmic localization of Kv7.4 channels (indicated with
black arrows, 40× magnification), n = 6 for MHN‐derived PHSKMC and n = 3 for MHS‐derived PHSKMC. (b) Western blotting reveals no
difference in Kv7.4 channel expression between PHSKMC derived from both MHN and MHS biopsies, n = 4 for MHN and n = 3 for MHS. Data
shown are the individual values with means SEM
VELLECCO ET AL. 7BJPGuide to PHARMACOLOGY 2017/18 (Alexander, Fabbro et al., 2017;
Alexander, Striessnig, et al., 2017).3 | RESULTS
3.1 | Primary human skeletal muscle cells derived
from MHN (negative patients) and MHS (susceptible
patients) biopsies do not reveal any difference in
morphology and in Kv7.4 channel expression
First, as shown in Figure 1a,b, no difference in morphological structure
and three‐dimensional organization of the fibres was found between
MHN and MHS biopsies. In PHSKMC derived from MHS and MHN
biopsies, immunohistochemistry analysis reveals a strong positivity of
SKM‐specific α‐actin, desmin, and myogenin as SKM markers (over
80% of cellular population) confirming the SKM phenotype (Figure 1c,d,e). Immunohistochemical techniques also revealed a clear cytoplas-
mic expression of Kv7.4 channels, the main subtype expressed in SKM
(Iannotti et al., 2013), in PHSKMC of both MHN‐ and MHS‐derived
biopsies (Figure 2a). Western blot analysis confirmed the presence of
Kv7.4 channels that is equally expressed in both MHN‐PHSKMC and
MHS‐PHSKMC (Figure 2b).3.2 | In PHSKMC derived from MHS biopsies
(susceptible subjects), activation of Kv7 channels
induces a paradoxical depolarizing response
In order to obtain a general pattern of the potassium channel activity
in these cells, the membrane‐hyperpolarizing or membrane‐
depolarizing effects of openers and blockers of different subtypes of
K+ channels were assayed. As expected, in MHN‐derived PHSKMC
(cells derived from negative biopsies), all the K+ channel activators
tested evoked a hyperpolarizing effect, even though with different
FIGURE 3 Activation of Kv7 channels induces a paradoxical depolarizing (DEP) response in primary human skeletal muscle cells (PHSKMC)
derived from malignant hyperthermia‐susceptible (MHS) biopsies (susceptible subjects). (a) Evaluation of activators and blockers of KATP, BKCa,
and Kv7 channels on the membrane potential of malignant hyperthermia‐negative (MHN)‐derived PHSKMC. As expected, the K channel activators
evoked a hyperpolarizing (HYP) effect, while the K channel blockers induced a DEP effect. (b) Evaluation of activators and blockers of KATP, BKCa,
and Kv7 potassium channels on the membrane potential of MHS‐derived PHSKMC reveals a significant reversal of the response to the Kv7
channel opener, retigabine, compared with that observed in PHSKMC fromMHN patients. Values shown are the mean (± SEM; n = 5) fluorescence
ratios recorded for HYP or DEP compounds during the experiment. Each experiment was carried out with six replicates. The asterisks indicate a
significant depolarizing difference from the effect evoked by vehicle (*P < .05). The symbol § indicates a significant hyperpolarizing difference from
the effect evoked by vehicle (§P < .05).
8 VELLECCO ET AL.BJPintensity, while all the K+ channel blockers induced a depolarizing
effect (Figure 3a). Interestingly, in MHS‐derived PHSKMC (cells
derived from susceptible subjects), this pattern was very different
(Figure 3b). In particular, the hyperpolarizing effects of both
cromakalim and NS1619 were significantly amplified. Surprisingly,
the effects of retigabine were completely reversed in MHS‐derived
cells, as this Kv7.4 channel activator evoked a paradoxical depolarizing
effect. However, the depolarizing profile of the K+ channel blockers in
MHS‐derived cells was conserved. Glibenclamide induced a modest
depolarization, while both iberiotoxin and XE991 evoked a very clear
depolarizing effect.3.3 | Retigabine triggers a contractile response in
samples from MHS (susceptible subjects) but not in
those from MHN (negative subjects)
To confirm the physiopathological relevance of the unexpected
depolarizing activity of Kv7 channels observed in MHS‐derived
PHSKMC following retigabine stimulation, for the whole
tissue, rather than an aspect of the cell culture, we exposed both
MHN and MHS bundles to retigabine, using the IVCT procedure.
As shown in Figure 4a, in MHN biopsies (negative patients),
retigabine, at concentration of 1 mM, did not affect tissue viabilityor changes in baseline tension within the assay time, that is,
15 min. Conversely, exposure of MHS biopsies (susceptible patients)
to retigabine (1 mM) increased baseline tension by more than 0.2 g,
mimicking the IVCT response elicited by the triggers used in IVCT in
susceptible patients (Figure 4b). Therefore, the phenomenon
observed in PHSKMC implies a key role for Kv7 channels located
on SKM.3.4 | H2S triggers an MHS‐like response to
retigabine in both MHN samples and in MHN‐derived
PHSKMC
To evaluate if an augmented H2S content could influence the contrac-
tility of SKM biopsies to retigabine, MHN tissues (negative patients)
were incubated with NaHS (3 mM for 5 min) or vehicle prior to addi-
tion of retigabine (1 mM, Figure 5a,b). Under these experimental con-
ditions, NaHS pretreatment leads to an increase of muscle contracture
following retigabine exposure, similar in onset and shape, to a typical
MHS response, showing more than 0.2‐g increase from baseline ten-
sion. When MHN samples were exposed to vehicle (H2O), used as a
control for NaHS, and challenged with retigabine, no change in base-
line tension was recorded (Figure 5a). To confirm that augmented
levels of H2S are causative of the paradoxical depolarizing activity
FIGURE 4 Retigabine triggers a contractile
response in malignant hyperthermia‐
susceptible (MHS; susceptible subjects) but
not in malignant hyperthermia‐negative
(MHN; negative subjects) biopsies. (a)
Representative trace of skeletal muscle
bundle obtained from MHN subjects
incubated with retigabine (1 mM) for 15 min.
(b) Representative trace of skeletal muscle
bundle obtained from MHS subjects
incubated with retigabine for 15 min.
Retigabine increases the contracture in MHS
but not in MHN bundles, n = 5 for MHN
biopsies and n = 4 for MHS biopsies. (c) Effect
of retigabine incubation, expressed as an
increased tension, in MHN and MHS biopsies.
The value enclosed in red circleindicates the
established threshold for susceptibility
diagnosis
VELLECCO ET AL. 9BJPobserved in MHS‐derived cells, MHN‐PHSKMC were incubated with
NaHS and then exposed to retigabine or XE991, selective Kv7.4 chan-
nel activator or blocker respectively. As shown in Figure 5d, in these
conditions, retigabine exerts a paradoxical depolarizing activity with
an analogue trend inversion on MHS‐derived cells.3.5 | Kv7 channels are persulfidated in MHS biopsies
To evaluate whether Kv7 channels could be differently expressed in
MHN (negative patients) and MHS (susceptible patients) biopsies,
real‐time PCR and western blot analysis for Kv7.4 channels protein
were performed. As shown in Figure 6a,b, there were no significant
differences in Kv7 mRNA (a) and protein (b) expression between
MHN and MHS biopsies. Moreover, no differences were detected
between MHN and MHS biopsies in the expression of all Kv7.4 chan-
nel subtypes (Figure S2). On the other hand, the persulfidation study
clearly shows that elevated signals for Kv7.4 channels were detectedin the MHS samples, in contrast to those in MHN samples. In detail,
the Kv7.4 channel protein contains only one highly nucleophilic cyste-
ine (Cys87) based on the prediction software Dianna 1.1. Therefore,
potential persulfidation of the Kv7.4 channels was addressed based
on a modified biotin switch assay, as previously described. The signal
was lost in the presence of a reducing agent DTT, confirming that
the detected signal is due to persulfidation (Figure 6c). These data
are in accordance with the higher levels of CBS‐derived polysulfides
(H2Sn) detected in MHS biopsies compared with those in the MHN
biopsies (Figure 6d).4 | DISCUSSION
In this study, we have investigated the involvement of the voltage‐
gated Kv7 channels in susceptibility to develop MH. The whole study
has been performed on human biopsies of vastus muscle obtained
from MH negative and MH susceptible patients, undergoing the IVCT
FIGURE 5 H2S triggers a malignant hyperthermia‐susceptible (MHS)‐like response to retigabine in both malignant hyperthermia‐negative (MHN)
biopsies and MHN‐derived PHSKMC. (a) Representative trace of skeletal muscle bundle obtained from MHN subjects incubated for 5 min with
vehicle (dH2O) followed by retigabine stimulation (1 mM). No increase in tension was observed. (b) Representative trace of skeletal muscle bundle
obtained from MHN subjects incubated for 5 min with NaHS (3 mM) followed by retigabine stimulation (1 mM). The increase in tension achieved
was similar to that for MHS samples, that is, >0.2 g above the resting tension. (c) Effect of NaHS (3 mM) or vehicle (dH2O) incubation in MHN
biopsies followed by retigabine stimulation. Values shown are the mean (± SEM; n = 5) increases in tension. *P < .05, significantly different from
vehicle. (d) Evaluation of retigabine and XE991, selective Kv7 potassium channel opener and blocker, respectively, on the membrane potential of
MHN‐PHSKMC incubated with NaHS. Retigabine exerts a paradoxical depolarizing activity in cells pretreated with NaHS with a similar trend
observed in MHS‐derived cells. No difference was detected between the two groups, following XE991. Values shown are the mean (± SEM; n = 5)
fluorescence ratios recorded during the experiment. Each experiment was carried out with six replicates. *P < .05, significantly different from
vehicle
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sies. This study stems from the original finding that SKM of MHS sub-
jects displays an augmented level of H2S and that such anomalous H2S
content is due to the overexpression of CBS. The increase in H2S con-
tributes to the SKM hypercontractility (Vellecco et al., 2016). Different
subtypes of potassium channels are known to be molecular targets for
H2S, such as KATP channels (Jiang, Tang, Cao, Wu, & Wang, 2010;
Lowicka & Beltowski, 2007) and small‐ and intermediate‐conductance
calcium‐activated K channels (SKCa and IKCa channels, respectively;
Li et al., 2010; Mustafa et al., 2011; Tang et al., 2013; Telezhkin
et al., 2010). Recently, Kv7 channels have been added as a new target
for H2S, and their activation accounts for H2S‐induced vasorelaxation
(Hedegaard et al., 2014; Hedegaard et al., 2016; Martelli et al., 2013)
and H2S‐induced protection against neuropathic pain (Di Cesare
Mannelli et al., 2017). It is known that Kv7 channels contribute to rest-
ing membrane potential and electrical excitation control of SKM
(Miceli et al., 2008; Roura‐Ferrer et al., 2008) and that the subtype
Kv7.4 channel has an essential role in the induction and maintenanceof differentiated state in skeletal myotubes in murine C2C12 myo-
blasts (Iannotti et al., 2010). In addition, exposure of human aortic
smooth muscle cells to H2S donors induces membrane hyperpolariza-
tion that is reversed by the Kv7 channel blocker XE‐991, suggesting
that interactions between H2S and Kv7 channels have a physiological
relevance to smooth muscle function (Martelli et al., 2013). All this evi-
dence indicates the Kv7 channels as potential players in the MH syn-
drome. As it is difficult to obtain human samples from individuals
susceptible to this rare syndrome, we have developed and character-
ized primary cell cultures (PHSKMC), derived from both MHN and
MHS biopsies. No significant change, in terms of cell morphology
and Kv7 expression, was detected between MHN‐derived PHSKMC
and MHS‐derived PHSKMC. However, when we evaluated the
membrane‐hyperpolarizing or depolarizing effects, exerted by openers
or blockers of KATP, BKCa, and Kv7 channel subtypes on MHS‐derived
PHSKMC, an anomalous activity of K+ channels was disclosed. Indeed,
the pattern of response obtained from MHN‐derived PHSKMC shows
the expected activity of the K+ channels: The openers cromakalim,
FIGURE 6 Kv7.4 channels are persulfidated in malignant hyperthermia‐susceptible (MHS) biopsies. (a) The mRNA levels of Kv7.4 are not
significantly different between malignant hyperthermia‐negative (MHN) and MHS biopsies, n = 5 for MHN and n = 6 for MHS. (b) Western
blotting reveals no significant difference between MHN and MHS biopsies, n = 7 for MHN and n = 8 for MHS. (c) Persulfidation analysis shows
that only in MHS biopsies Kv7.4 S–SH is detected, and no band has been observed in MHN biopsies. DTT, a reducing agent, has been used to
eliminate the modification prior to detection. Data shown are the individual values with means ± SEM from n = 6 experiments in each group.
*P < .05, significantly different as indicated. (d) Evaluation of CBS‐derived polysulfides (H2Sn) levels in tissue homogenates reveals a significant
increase in MHS samples compared with MHN samples. Data shown are the individual values with means ± SEM; n = 6 for each group. *P < .05,
significantly different as indicated
VELLECCO ET AL. 11BJPNS1619, and retigabine induce hyperpolarization, while the blockers
glibenclamide, NS1619, and XE991 induce depolarization. When the
same experiment has been performed in MHS‐derived PHSKMC, the
pattern of results was markedly different: The signals induced by the
K+ channel opener retigabine (Kv7 channel opener) was switched to
depolarizing activity, while cromakalim (KATP opener) and NS1619
(BKCa opener) displayed an enhanced hyperpolarizing activity. This
behaviour implies, most likely, a compensatory effect to counterbal-
ance the reversed activity of Kv7 channels. On the basis of the above
observations, in SKM cells of MHS individuals, Kv7 activation would
be expected to induce muscle contraction instead of muscle relaxa-
tion. The finding that, although in MHS biopsies Kv7.4 channel activity
is strongly perturbed by persulfidation, no difference was detected
between MHN and MHS SKM morphology implies an “alternative”
pattern of differentiation of MHS SKM in order to maintain the phys-
iological status of the tissue.Next, we challenged MHS bundles with retigabine using the IVCT
procedures. The presence of a consistent significant contracting effect
induced by retigabine per se in MHS biopsies (susceptible patients)
confirms a switch of the physiological response following Kv7 activa-
tion. In particular, retigabine‐induced increase in baseline tension
exceeds 0.2 g; this value represents the threshold used in IVCT, fol-
lowing addition of triggers, to diagnose MH susceptibility. In contrast,
no change in baseline tension was observed when retigabine, as well
as IVCT triggers, were added to MHN bundles. It is important to high-
light that the concentration ranges used are in line with IVCT guide-
lines that aim to achieve better reproducibility of the response for
fulfilment of the quality criteria with consequent patient safety (Hop-
kins et al., 2015). We have previously shown that incubation of MHN
biopsies with NaHS, followed by addition of the triggers used in IVCT
(caffeine and halothane), leads to an increase of muscle contracture
that is typical of MHS biopsies (over 0.2 g from baseline tension;
12 VELLECCO ET AL.BJPVellecco et al., 2016). Following the same protocol, MHN (negative
patients) biopsies exposed to NaHS prior to challenge with retigabine
display an increase in baseline tension. The shape and magnitude of
the contracture elicited are similar to those obtained in MHS (suscep-
tible patients) challenged with retigabine only. This finding implies that
the high levels of H2S, present locally in the SKM of MHS susceptible
patients (Vellecco et al., 2016), affect Kv7 activity. Indeed, H2S incuba-
tion can induce, in MHN samples, a switch of the response to
retigabine into the MHS‐like response. To obtain further evidence
on the mechanisms so far described, we used MHN‐derived PHSKMC
incubated with NaHS or vehicle (H2O) and then stimulated with
retigabine. The results clearly show that in cells pretreated with NaHS,
retigabine evokes a depolarizing activity. These results obtained from
PHSKMC clearly reproduce the effect observed, using the IVCT diag-
nostic procedure.
The data presented here, taken together with our previous study
(Vellecco et al., 2016), suggest that in patients with MH, the aug-
mented levels of CBS‐derived H2S, within the SKM, induce an anom-
alous behaviour of Kv7 channels reversing its normal, physiological
hyperpolarizing activity into depolarization. This molecular event
induces a hypercontractility of SKM that, most likely, contributes to
muscle rigidity, one of the early clinical signs of MH syndrome. How-
ever, how H2S can affect Kv7 channels is still to be addressed.
Changes in Kv7 mRNA expression and protein content are not
involved, as demonstrated by the RT‐PCR and Western blot analysis
performed on both MHN and MHS biopsies, confirming the data
obtained by immunohistochemistry.
In the recent relevant reports, one broad post‐translational effect
of H2S that affects biological function is the sulfhydration or
persulfidation of target proteins (Paul & Snyder, 2012; Zhang, Du,
Tang, Huang, & Jin, 2017). Several proteins that participate in a variety
of physiological and/or pathological processes, such as cell
proliferation/survival, mitochondrial bioenergetics, vascular reactivity
and atherogenesis, and oxidative stress and inflammation are recog-
nized as targets for sulfhydration (Bibli, Hu, et al., 2018; Jiang et al.,
2010; Módis et al., 2016; Mustafa et al., 2009; Mustafa et al., 2011;
Zhao, Li, Wu, Lai, & Yang, 2014). In this context, Kv7 channels have
been recently proposed to be redox sensitive. In particular, highly
nucleophilic cysteine residues can be oxidized by hydrogen peroxide
to sulfenic (SOH) acid, to sulfinic (SO) acid, and finally to sulfonic
(SO2) acid (Sahoo et al., 2014). Depending on the extent of oxidation,
such modified cysteines will affect the channel activity. Therefore, we
have explored the possibility that CBS‐derived H2S or H2Sn could
induce post‐translational modifications affecting Kv7 channel function.
The data clearly show that, only in MHS (susceptible patients) biop-
sies, the Kv7.4 channels were persulfidated. This evidence is compati-
ble with the finding that MHS samples exhibit increased CBS activity
in the presence of its substrates, as demonstrated by higher H2Sn
bioavailability.
In conclusion, we have demonstrated that in SKM of MHS
patients, CBS‐derived H2S drives persulfidation of Kv7 channels. This
post‐translational event markedly changed the Kv7 channel signalling,
switching its normal hyperpolarizing activity into a depolarizing effect.This molecular event translates in a pathological hypercontractility of
SKM, typical of the MH syndrome. Therefore, Kv7 channels can be
added to the target proteins for persulfidation–sulfhydration. This
experimental finding may have a clinical utility as it may be possible
to use, as the diagnostic marker, the CBS content and/or CBS‐derived
polysulfides, using needle biopsies rather than a 2‐ to 3‐cm length of
vastus muscle. In addition, retigabine could be used as trigger in the
IVCT procedure to identify a subcluster of patients where Kv7 chan-
nels play a major role. Further studies will be necessary to confirm if
retigabine could substitute for halothane and caffeine in the IVCT
diagnostic test.
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